Efficacy of miglitol on glycemic control in type 2 diabetes with insufficient basal insulin therapy - combination therapy of BOT and miglitol

Dept of Medicine, Metabolisma and Endocrinology Juntendo University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2010年8月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) type 1 diabetes 2) patients who have serious liver disease (AST and/or ALT are more than 100IU/L) 3) patients who have serious kidney disease (Serum Cr is more than 2.0mg/dL) 4) patients who have serious heart disease ( patients who have apparent heartfailure or myocardial infarction within 3 months) 5) patients who have serious pancreatic disease 6) patients with cancer 7) anemic patients (Hb is less than 11g/dL) 8) patients with thrombocytepenia (Platelet count is less than 100000/mm3) 9) patients with serious diabetic complications including progressed neutopathy and proliferative retinopathy 10) patietns with serious infection, inflammation, or injuary. pre- or post- operative state 11) patients who have inflammatory bowel disease, ulcer in bowel, ileus and high risk for ilus 12) patinets with chronic bowel diseases which have probability to induce malabsorption syndrome 13) patients who has the disease which is deteriorated with increase of gas in bowel 14) patients who have histroy of gastrectomy 15) patients with intolerance in Lactose 16) heavy alcohol drinker (patients who drink more than 480mL of Japanese Sake, 2L of beer, 180mL of whisky, 360mL of wine, or 360mL of Shochu per day) 17) patients who are pregnant, hope to be pregnant, or are in lactation period 18) patients who have viral infection (HBV,HCV) 19) patients who are not applicable to this study judged by the medical doctor.

发起方

Dept of Medicine, Metabolisma and Endocrinology Juntendo University Graduate School of Medicine